Kymriah IV injection contains Chisagenreclucel (YJ code: 4900402X1020, per patient) and is manufactured by Novartis Pharma. This is a CAR T-cell therapy used to treat certain types of B-cell lymphomas and acute lymphoblastic leukemia.
Kymriah IV injection
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).